 |
|
|
| |
Patient characteristics and efficacy of pangenotypic direct-acting antiviral regimens among a cohort of chronic hepatitis C patients receiving routine clinical care in the U.S.
|
| |
| |
AASLD 2020 Nov 11-16 virtual
Reported by Jules Levin
Stuart C. Gordon MD1,2, Jia Li PhD 3, Anne C. Moorman MPH RN 4, Philip R. Spradling MD 4, Eyasu H. Teshale MD 4, Joseph A. Boscarino PhD MPH5, Yihe G. Daida PhD 6, Mark A. Schmidt PhD MPH 7, Yueren Zhou MS , Loralee B. Rupp MS MBA 8, Sheri Trudeau MPH 3, and Mei Lu PhD 3
1Division of Gastroenterology and Hepatology, Henry Ford Health System, Detroit MI; 2School of Medicine, Wayne State University, Detroit MI; 3Department of Public Health Sciences, Henry Ford Health System, Detroit MI; 4Division of Viral Hepatitis, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta GA; 5Department of Population Health Sciences, Geisinger Clinic, Danville PA; 6Center for Integrated Health Care Research, Kaiser Permanente-Hawai'i, Honolulu HI; 7Center for Health Research, Kaiser Permanente-Northwest, Portland OR; 8Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit MI.
|
| |
|
|
|
|
|
